Indeed, the therapeutic effect of anti-PD-1 therapy can be attributed partially to the targeting of innate immune cells as shown by increased survival of transgenic glioma models harboring CD8 gene deletion treated with this immunotherapy [40]. This evidence concerns the gene PDCD1 and central nervous system cancer.